David Dai
Stock Analyst at Bernstein
(2.21)
# 2,806
Out of 5,147 analysts
32
Total ratings
44.83%
Success rate
-0.34%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASML ASML Holding | Maintains: Outperform | $1,528 → $1,642 | $1,450.56 | +13.20% | 2 | Jan 22, 2026 | |
| SONY Sony Group | Maintains: Outperform | $33 → $30 | $23.06 | +30.10% | 1 | Jan 14, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $5.40 | +29.63% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $8.73 | +83.28% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $110.23 | +6.14% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $21.71 | +75.03% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $101.95 | +29.48% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $7.25 | +175.86% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $15.97 | +62.81% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $16.59 | +80.83% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $2 | $3.86 | -48.19% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $15.50 | +54.84% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $32.30 | -25.70% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $13.61 | +406.98% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $32.20 | +55.28% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $58.80 | +2.04% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $7.25 | +6,079.31% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $74.13 | -46.04% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.99 | +1,910.05% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.70 | +1,751.85% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $26.53 | +96.00% | 1 | Mar 17, 2020 |
ASML Holding
Jan 22, 2026
Maintains: Outperform
Price Target: $1,528 → $1,642
Current: $1,450.56
Upside: +13.20%
Sony Group
Jan 14, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $23.06
Upside: +30.10%
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $5.40
Upside: +29.63%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $8.73
Upside: +83.28%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $110.23
Upside: +6.14%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $21.71
Upside: +75.03%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $101.95
Upside: +29.48%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $7.25
Upside: +175.86%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $15.97
Upside: +62.81%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $16.59
Upside: +80.83%
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $3.86
Upside: -48.19%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $15.50
Upside: +54.84%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $32.30
Upside: -25.70%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $13.61
Upside: +406.98%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $32.20
Upside: +55.28%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $58.80
Upside: +2.04%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $7.25
Upside: +6,079.31%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $74.13
Upside: -46.04%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.99
Upside: +1,910.05%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.70
Upside: +1,751.85%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $26.53
Upside: +96.00%